Market Outlook

The global AI in clinical trials market, valued at USD 3.48 billion in 2025, is projected to reach USD 3.96 billion in 2026 and USD 11.61 billion by 2035, representing a CAGR of 12.7% during the forecast period 2026 to 2035.

See What’s in the Full Report – Request Your Complimentary Insights!

Market Report: Key Takeaways

Market Size & Trends

In terms of trial phase, phase II holds the largest share (nearly 55%) of the current market.
With respect to type of offering, services segment dominates the current market.
Based on the deployment mode, cloud-based AI solutions capture the largest share (around 75%) of the current market, and the trend is unlikely to change in the future.
In terms of therapeutic area, oncological disorders are expected to hold the largest market share (more than 40%) by 2035.
With respect to technology exposure, machine learning dominates the current market.
Based on end-user, biotechnology and pharmaceutical companies capture the largest share of the current market, and the trend is unlikely to change in the future.
In terms of geographical region, the Asia-Pacific region dominates the current market by securing over 40% share within the AI in clinical trials industry.

Key Market Statistics

Market Size in 2026: $3.96 Billion
Estimated Market Size in 2035: $11.61 Billion
CAGR (Till 2035): 12.7%
Asia-Pacific: Largest market in 2026
Asia-Pacific: Fastest growing region

Market Introduction

The global AI in clinical trials market is expanding rapidly, driven by the growing demand for improved patient recruitment and retention, real-time data collection, and enhanced cost and data efficiencies. Rising investment activity and cross-industry partnerships are further broadening opportunities in this domain. In parallel, clinical trial software centralizes patient, site, operational and outcome data across decentralized and conventional studies.

Clinical trials account for nearly half of the time and capital expenditure in the drug development process. However, over the past few decades, the success rate of a drug candidate advancing from conventional clinical trials to marketing approval has remained relatively constant at approximately 10%, placing considerable financial burden on sponsors and causing significant delays in bringing therapies to market. Key challenges contributing to this low success rate of conventional trials include inadequate study design, incomplete patient recruitment, improper subject stratification, and high participant attrition.

To address these challenges, stakeholders have increasingly turned to AI to streamline clinical trial processes. Artificial intelligence enables integration and analysis of large data volumes, helping sponsors optimize trial design, improve site selection, enhance patient stratification, and refine treatment evaluation, ultimately strengthening the entire drug development continuum. As regulatory agencies, such as the FDA and EMA continue to develop frameworks accommodating AI-driven trial methodologies, institutional confidence in these tools is growing, positioning AI as a foundational element of next-generation clinical research rather than a supplementary capability.

Market Segmentation

Based on the research, we have segmented the AI in Clinical Trials Market into trial phase, type of offering, deployment mode, therapeutic area, technology exposure, end-user and geographical regions.

Distribution by Trial Phase

Phase I
Phase II
Phase III

Distribution by Type of Offering

Software
Services

Distribution by Deployment Mode

Cloud-based
On-premises

Distribution by Therapeutic Area

Oncological Disorders
Infectious Diseases
CNS disorders
Metabolic Disorders
Immunological Disorders
Cardiovascular Disorders
Other Disorders

Distribution by Technology Exposure

Machine Learning
Molecular Modeling and Simulation
Deep Learning
Omics Integration
Generative Model
Other Technologies

Distribution by End-user

Biotechnology and Pharmaceutical Companies
Academic Research Institutes
Other End-users

Distribution by Geographical Regions

North America
- US
- Canada
Europe
- UK
- Germany
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- South Korea
- Australia
- India
Middle East and North Africa
- Saudi Arabia
- UAE
- Egypt
Latin America
- Brazil
- Mexico
- Argentina

Your Business is Unique – Why Shouldn’t Your Report Be?

AI in Clinical Trials Market Key Insights

What are the Key Drivers for AI in Clinical Trials Market Growth?

Improved Patient Retention Rate: AI helps address key challenges patients face, such as frequent site visits, time constraints, and associated costs. By leveraging AI, sponsors can reduce the need for physical travel by enabling remote participation across multiple trial stages, ultimately lowering the overall time and financial commitment for patients. Moreover, telehealth platforms integrated within AI-enabled trial frameworks allow healthcare professionals to conduct regular follow-ups and monitor patient activity with greater consistency.
Real-time Data Collection: The widespread adoption of mobile applications, wearable medical devices, and telemedicine, now enables continuous, real-time collection of patient data throughout the course of a clinical trial. This capability allows healthcare professionals to monitor patient health more accurately, identify emerging trends, and make timely adjustments to study protocols, thereby improving overall research quality. Beyond data collection, these technologies have also streamlined ancillary trial processes, including patient recruitment, retention, and data management, contributing to enhanced trial efficiency with electronic health records. The growing recognition of these benefits is accelerating the adoption of AI in clinical trials. Within this workflow, digital twins in healthcare create data-driven virtual representations for patient, device and clinical-process simulation.

What are the Main Challenges for AI in Clinical Trials Market Growth?

Inaccuracy and Human Dependency: AI models deployed in trial settings can at times generate incomplete or inaccurate results, producing flawed simulations and incorrect predictions that may compromise the integrity of study outcomes. Given that clinical trials directly inform therapeutic decisions and patient safety protocols, such inaccuracies carry significant consequences, making it essential for healthcare professionals to independently validate AI-generated findings before acting on them.
Interoperability and Data Integration Complexity: The fragmented data landscape restricts the flow of information between healthcare providers, along with limiting the depth and quality of insights that AI tools can generate. As a result, additional data normalization, tuning, and engineering are often required before meaningful analysis is possible. The absence of universally accepted data standards worsens this challenge, as AI models trained on heterogeneous inputs become more prone to inconsistencies that undermine both model performance and trial reliability.

What are the Regulatory Guidelines for the Usage of AI in Clinical Trials from Different Regulatory Bodies?

The USFDA Guidance: The FDA’s draft guidance related to the usage of AI to support regulatory decision-making outlines a seven-step risk-based credibility assessment for AI models. Higher-risk AI applications, particularly those that can affect patient safety or trial efficacy will require rigorous validation, documentation of model training, and lifecycle monitoring with tools like Algorithm Change Protocols. Moreover, sponsors must demonstrate AI reliability for specific contexts of use-cases, including trial design, recruitment, and data analysis.
EMA and EU Frameworks: The EMA and EU frameworks support the utilization of AI in clinical trials through its Big Data Strategy. The strategy focuses on automation, insights, and decision support while managing risks. Notably, the EU AI Act classifies AI used in clinical trials as risky, requiring stringent requirements like transparency in decision logic and compliance for medical devices. Additionally, sponsors must ensure ethical data handling and obtain regulatory approvals before deploying AI.

Recent Developments in AI in Clinical Trials Market

In March 2026, PhaseV launched the AI Conductor centralized platform in order to automate all the clinical trial steps, from drafting protocols to submitting final reports.
In March 2026, NetraMark announced new findings from its proprietary AI platform, NetraAI, that uncovered clinically meaningful responder subgroups within the landmark anti-amyloid treatment in asymptomatic alzheimer’s disease (A4) trial.
In January 2026, Accenture acquired Faculty to scale Accenture’s capabilities to help its healthcare clients reinvent core and critical business processes with safe and secure AI solutions that result in tangible outcomes.
In October 2025, Thermo Fisher Scientific and OpenAI entered into an agreement to embed advanced artificial intelligence across its clinical trials business in order to accelerate drug development, simplifying the research processes to get medicines to patients faster and more cost-effectively.

Industry Experts on AI in Clinical Trial Market

The market for AI in clinical trials has a transformative future and is likely to remain progressive in the future. Highlighting this trend, Jennifer Duff (Executive Vice President and General Manager of Zelta), stated that, “AI is going to optimize efficiency, bring down costs and manual effort, and improve traceability and quality. It will also bring together really good science between the human experts and the added controls on the AI side. There’s a significant amount of investment in this domain right now. Once we stand up the ability to support ingestion and implementation of this, and integrate with downstream workflows, that adoption will add immediate value.”

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes transcripts of the interviews conducted with the following individuals:

Co-founder, Chief Executive Officer and Chief Technology Officer, Small Company, Switzerland
Founder and Chief Executive Officer, Mid-Sized Company, US
Founder and Chief Executive Officer, Small Company, US
Co-founder and Executive Director, Mid-Sized Company, US
Chief Technology Officer, Chief Commercial Officer, Chief Delivery Officer, Mid-Sized Company, Head of Marketing, Mid-Sized Company, US

In addition, the market report includes transcripts of the following third-party discussions:

Chief Science Officer, Large Company, US; Co-Founder and Chief Executive Officer, Mid-Sized Company, US; Chief Executive Officer, Mid-Sized Company, US; Associate Professor and Blue Cross California Distinguished Professor, Large Organization, US
EVP, Chief Information, Technology, and Product Officer, Large Company, US
Co-Founder and Chief Executive Officer, Mid-Sized Company, US
Chief Technology Officer, Mid-Sized Company, US
Director of the Office of Medical Policy (CDER), Large Organization, US
Professor of Medicine, Large Organization, US; Program Manager, Large Organization, US; Director, Bioethics Lead, Large Company, US; Associate Dean, Human Research Protections and Director of the Human Research Protections Program, Large Organization, US; Executive IRB Chair and VP of IBC Affairs, Large Company, US
Hematologist, AI Specialist, and Research Group Leader, Large Organization, Germany
Cardiologist and Associate Director of the Accelerator for Clinical Transformation Research Group, Large Organization, US
Heart Failure Cardiologist and Researcher, Large Organization, US
Senior Community Development Manager, Mid-Sized Company, Netherlands

Pay Only for What You Need – The Best Way to Optimize

Which Trial Phase Holds the Largest Share in AI in Clinical Market?

In 2026, the phase II clinical trials hold the highest market share (around 55%). This growth can be attributed to various advantages offered by AI solutions in phase II clinical trials (considered a critical decision point) where companies assess proof-of-concept, optimal dosing, and efficacy in larger patient groups, with traditional success rates of only 30-40%.
The market for phase III clinical trials is likely to grow at a higher CAGR during the forecast period due to the generation of large amounts of data (up to 3.6 million data points per study), which necessitates the use of advanced AI for real-time analysis, risk monitoring and adaptive designs to manage complexity and reduce costs.

AI in Clinical Trial Market Share by Trial Phase, 2026

Regional Analysis: Which Regions are Showing the Fastest Growth in AI in Clinical Trials Industry?

Asia-Pacific: Dominating the Market by Securing Highest Share

According to our projections, Asia-Pacific holds the largest (over 40%) share of the current global AI in clinical trials market. Further, the Asia-Pacific region is poised to grow at a relatively faster pace (CAGR of 13.6%) through 2035. Several factors, such as rapid digital infrastructure expansion, growing clinical trial activity, rising investments from large pharmaceutical companies are fueling the AI in clinical trials market growth in this region. Countries like China, India, Japan, and South Korea are leading this expansion through rapid digital transformation and a thriving tech ecosystem.

Will Oncological Disorders Hold the Largest Share within the AI in Clinical Trials Industry Through 2035?

By 2035, the oncological disorders segment is likely to hold the largest share (nearly 50%) within the AI in clinical trials market. Further, this segment is expected to witness a significant growth rate during the forecast period.
This trend is largely driven by the extensive data volume and inherent complexity of oncology clinical trials, creating a strong use case for AI-driven analytics, patient stratification, and decision support.

AI in Clinical Trial Market Share by Therapeutic Area, 2035

Which End-user Holds for the Largest Share of the AI in Clinical Trials Market?

In the current year, the biotechnology and pharmaceutical companies segment occupies the higher market share, owing to the growing collaborations, dedicated resources, and strong capabilities in the AI in clinical trials domain.
The market for biotechnology and pharmaceutical companies is also expected to grow at a higher CAGR, due to their substantial R&D investments, access to extensive proprietary datasets, and strategic focus on accelerating drug development timelines through AI integration.

What is the Market Opportunity for Technology Exposure?

Based on the AI in clinical trials market forecast, machine learning technology holds the largest share within the current global market. This dominance is due to its superior versatility in handling complex clinical datasets, enabling predictive modeling, and real-time insights.
In addition to this, we anticipate the generative model segment to witness a higher CAGR through 2035. Generative models create realistic synthetic patient data, which drives faster adoption and higher growth compared to other technology segments.

Which Type of Offering Holds the Largest Share in the AI in Clinical Market?

In the current year, the services segment occupies the highest market share due to the growing demand for outsourcing and specialized expertise in implementing AI solutions across clinical trials.
Conversely, the software segment is likely to grow at a higher CAGR during the forecast period till 2035, due to the advancements in scalable AI platforms, and cloud-based solutions, that enable integration and long-term adoption across clinical trial processes.

Which Deployment Mode Dominates the AI in Clinical Trials Market?

Cloud-based deployment of AI in clinical trials currently dominates the market, accounting for the largest share (around 75%) due to its scalability, cost efficiency, and ability to support collaboration across distributed trial stakeholders. This segment is also expected to grow at an accelerated pace through 2035, driven by the growing adoption of decentralized trial models and the rising need to manage large, complex, and data-intensive AI applications.

Get an Instant Quote in 10 Minutes. Lowest Price Guaranteed

Scope of AI in Clinical Trials Market Report

Key Report Attribute	Details
Historical Trend	Since 2022
Forecast Period	Till 2035
Market Size 2026	$ 3.96 Billion
Market Size 2035	$ 11.61 Billion
CAGR (Till 2035)	12.7%
Segments Covered	Trial Phase Type of Offering Deployment Mode Therapeutic Area Technology Exposure End-user Geographical Regions
Key Players	Clarivate ConcertAI IQVIA LabCorp Medidata Microsoft PathAI ServiceNow Signant Health TransPerfect Life Sciences (A complete list of players captured is available in the report)
PowerPoint Presentation (Complimentary)	Available
Customization Scope	15% Free Customization
Excel Data Packs (Complimentary)	Available

+ 1. PREFACE

1.1. Introduction

1.2. Report Coverage

1.3. Market Segmentation

1.4. Key Market Insights

1.5. Market Share Insights

1.6. Key Questions Answered

+ 2. RESEARCH METHODOLOGY

2.1. Chapter Overview

2.2. Research Assumptions

2.2.1. Market Landscape and Market Trends

2.2.2. Market Forecast and Opportunity Analysis

2.2.3. Comparative Analysis

2.3. Database Building

2.3.1. Data Collection

2.3.2. Data Validation

2.3.3. Data Analysis

2.4. Project Methodology

2.4.1. Secondary Research

2.4.1.1. Annual Reports

2.4.1.2. Academic Research Papers

2.4.1.3. Company Websites

2.4.1.4. Investor Presentations

2.4.1.5. Regulatory Filings

2.4.1.6. White Papers

2.4.1.7. Industry Publications

2.4.1.8. Conferences and Seminars

2.4.1.9. Government Portals

2.4.1.10. Media and Press Releases

2.4.1.11. Newsletters

2.4.1.12. Industry Databases

2.4.1.13. Roots Proprietary Databases

2.4.1.14. Paid Databases and Sources

2.4.1.15. Social Media Portals

2.4.1.16. Other Secondary Sources

2.4.2. Primary Research

2.4.2.1. Types of Primary Research

2.4.2.1.1. Qualitative Research

2.4.2.1.2. Quantitative Research

2.4.2.1.3. Hybrid Approach

2.4.2.2. Advantages of Primary Research

2.4.2.3. Techniques for Primary Research

2.4.2.3.1. Interviews

2.4.2.3.2. Surveys

2.4.2.3.3. Focus Groups

2.4.2.3.4. Observational Research

2.4.2.3.5. Social Media Interactions

2.4.2.4. Key Opinion Leaders Considered in Primary Research

2.4.2.4.1. Company Executives (CXOs)

2.4.2.4.2. Board of Directors

2.4.2.4.3. Company Presidents and Vice Presidents

2.4.2.4.4. Research and Development Heads

2.4.2.4.5. Technical Experts

2.4.2.4.6. Subject Matter Experts

2.4.2.4.7. Scientists

2.4.2.4.8. Doctors and Other Healthcare Providers

2.4.2.5. Ethics and Integrity

2.4.2.5.1. Research Ethics

2.4.2.5.2. Data Integrity

2.4.3 Analytical Tools and Databases

2.5. Robust Quality Control

+ 3. MARKET DYNAMICS

3.1. Chapter Overview

3.2. Forecast Methodology

3.2.1. Top-down Approach

3.2.2. Bottom-up Approach

3.2.3. Hybrid Approach

3.3. Market Assessment Framework

3.3.1 Total Addressable Market (TAM)

3.3.2. Serviceable Addressable Market (SAM)

3.3.3. Serviceable Obtainable Market (SOM)

3.3.4. Currently Acquired Market (CAM)

3.4. Forecasting Tools and Techniques

3.4.1. Qualitative Forecasting

3.4.2. Correlation

3.4.3. Regression

3.4.4. Extrapolation

3.4.5. Convergence

3.4.6. Sensitivity Analysis

3.4.7. Scenario Planning

3.4.8. Data Visualization

3.4.9. Time Series Analysis

3.4.10. Forecast Error Analysis

3.5. Key Considerations

3.5.1. Demographics

3.5.2. Government Regulations

3.5.3. Reimbursement Scenarios

3.5.4. Market Access

3.5.5. Supply Chain

3.5.6. Industry Consolidation

3.5.7. Pandemic / Unforeseen Disruptions Impact

3.6. Limitations

+ 4. MACRO-ECONOMIC INDICATORS

4.1. Chapter Overview

4.2. Market Dynamics

4.2.1. Time Period

4.2.1.1. Historical Trends

4.2.1.2. Current and Forecasted Estimates

4.2.2. Currency Coverage

4.2.2.1. Major Currencies Affecting the Market

4.2.2.2. Factors Affecting Currency Fluctuations on the Industry

4.2.2.3. Impact of Currency Fluctuations on the Industry

4.2.3. Foreign Currency Exchange Rate

4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market

4.2.3.2. Strategies for Mitigating Foreign Exchange Risk

4.2.4. Recession

4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market

4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt

4.2.5. Inflation

4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy

4.2.5.2. Potential Impact of Inflation on the Market Evolution

4.2.6. Interest Rates

4.2.6.1. Interest Rates and Their Impact on the Market

4.2.6.2. Strategies for Managing Interest Rate Risk

4.2.7. Commodity Flow Analysis

4.2.7.1. Type of Commodity

4.2.7.2. Origins and Destinations

4.2.7.3. Values and Weights

4.2.7.4. Modes of Transportation

4.2.8. Global Trade Dynamics

4.2.8.1. Import Scenario

4.2.8.2. Export Scenario

4.2.8.3. Trade Policies

4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers

4.2.8.5. Impact of Trade Barriers on the Market

4.2.9. War Impact Analysis

4.2.9.1. Russian-Ukraine War

4.2.9.2. Israel-Hamas War

4.2.10. COVID Impact / Related Factors

4.2.10.1. Global Economic Impact

4.2.10.2. Industry-specific Impact

4.2.10.3. Government Response and Stimulus Measures

4.2.10.4. Future Outlook and Adaptation Strategies

4.2.11. Other Indicators

4.2.11.1. Fiscal Policy

4.2.11.2. Consumer Spending

4.2.11.3. Gross Domestic Product

4.2.11.4. Employment

4.2.11.5. Taxes

4.2.11.6. Stock Market Performance

4.2.11.7. Cross Border Dynamics

4.3. Conclusion

+ 5. EXECUTIVE SUMMARY

+ 6. INTRODUCTION

6.1. Chapter Overview

6.2. Evolution of AI

6.3. Subfields of AI

6.4. Applications of AI in Healthcare

6.4.1. Drug Discovery

6.4.2. Drug Manufacturing

6.4.3. Marketing

6.4.4. Diagnosis and Treatment

6.4.5. Clinical Trials

6.5. AI in Clinical Trials

6.6. Challenges Associated with the Adoption of AI

6.7. Future Perspective

+ 7. MARKET LANDSCAPE

7.1. Chapter Overview

7.2. AI in Clinical Trials: AI Software and Service Providers Landscape

7.2.1. Analysis by Year of Establishment

7.2.2. Analysis by Company Size

7.2.3. Analysis by Location of Headquarters

7.2.4. Analysis by Company Size and Location of Headquarters (Region)

7.2.5. Analysis by Key Offerings

7.2.6. Analysis by Deployment Options

7.2.7. Analysis by Type of AI Technology Used

7.2.8. Analysis by End-user

7.2.9. Analysis by Application Area

+ 8. COMPANY PROFILES

8.1. Chapter Overview

8.2. Clarivate*

8.2.1. Company Overview

8.2.2. Financial Information

8.2.3. Offerings Portfolio

8.2.4. Recent Developments and Future Outlook

* Similar details are presented for other companies mentioned below (based on information in the public domain)

8.3. ConcertAI

8.4. IQVIA

8.5. LabCorp

8.6. Medidata

8.7. Microsoft

8.8. PathAI

8.9. ServiceNow

8.10. Signant Health

8.11. TransPerfect Life Sciences

+ 9. CLINICAL TRIAL ANALYSIS

9.1. Chapter Overview

9.2. Scope and Methodology

9.3. AI in Clinical Trials

9.3.1. Analysis by Trial Registration Year

9.3.2. Analysis by Number of Patients Enrolled

9.3.3. Analysis by Trial Phase

9.3.4. Analysis by Trial Status

9.3.5. Analysis by Trial Registration Year and Status

9.3.6. Analysis by Type of Sponsor

9.3.7. Analysis by Patient Gender

9.3.8. Analysis by Patient Age

9.3.9. Word Cloud Analysis: Emerging Focus Areas

9.3.10. Analysis by Target Therapeutic Area

9.3.11. Analysis by Study Design

9.3.11.1. Analysis by Type of Patient Allocation Model Used

9.3.11.2. Analysis by Type of Trial Masking Adopted

9.3.11.3. Analysis by Type of Intervention

9.3.11.4. Analysis by Trial Purpose

9.3.12. Most Active Players: Analysis by Number of Clinical Trials

9.3.13. Analysis of Clinical Trials by Geography

9.3.14. Analysis of Clinical Trials by Geography and Trial Status

9.3.15. Analysis of Patients Enrolled by Geography and Trial Registration Year

9.3.16. Analysis of Patients Enrolled by Geography and Trial Status

+ 10. PARTNERSHIPS AND COLLABORATIONS

10.1. Chapter Overview

10.2. Partnership Models

10.3. AI in Clinical Trials: Partnerships and Collaborations

10.3.1. Analysis by Monthly Trend of Partnership

10.3.2. Analysis by Type of Partnership

10.3.3. Analysis by Type of Partner

10.3.4. Most Active Players: Analysis by Number of Partnerships

10.3.5. Analysis by Geography

10.3.5.1. Local and International Agreements

10.3.5.2. Intracontinental and Intercontinental Agreements

+ 11. FUNDING AND INVESTMENT ANALYSIS

11.1. Chapter Overview

11.2. Funding Models

11.3. AI in Clinical Trials: Funding and Investments

11.3.1. Analysis of Instances by Month-Year of Funding

11.3.2. Analysis of Amount Invested by Month-Year of Funding

11.3.3. Analysis of Instances by Type of Funding

11.3.4. Analysis of Amount Invested by Type of Funding

11.3.5. Analysis by Geography

11.3.6. Most Active Players: Analysis by Number of Funding Instances

11.3.7. Leading Investors: Analysis by Number of Funding Instances

11.4. Concluding Remarks

+ 12. BIG PHARMA INITIATIVES

12.1. Chapter Overview

12.2. Scope and Methodology

12.3. Analysis by Year of Initiative

12.4. Analysis by Type of Initiative

12.5. Analysis by Application Area of AI

12.6. Analysis by Target Therapeutic Area

12.7. Benchmarking Analysis: Big Pharma Players

+ 13. AI IN CLINICAL TRIALS: USE CASES

13.1. Chapter Overview

13.2. Use Case 1: Collaboration between Roche and AiCure

13.2.1. Roche

13.2.2. AiCure

13.2.3. Business Needs

13.2.4. Objectives Achieved and Solutions Provided

13.3. Use Case 2: Collaboration between Takeda and AiCure

13.3.1. Takeda

13.3.2. AiCure

13.3.3. Business Needs

13.3.4. Objectives Achieved and Solutions Provided

13.4. Use Case 3: Collaboration between Teva Pharmaceuticals and Intel

13.4.1. Teva Pharmaceuticals

13.4.2. Intel

13.4.3. Business Needs

13.4.4. Objectives Achieved and Solutions Provided

13.5. Use Case 4: Collaboration between Undisclosed Pharmaceutical Company and Antidote

13.5.1. Antidote

13.5.2. Business Needs

13.5.3. Objectives Achieved and Solutions Provided

13.6. Use Case 5: Collaboration between Undisclosed Pharmaceutical Company and Cognizant

13.6.1. Cognizant

13.6.2. Business Needs

13.6.3. Objectives Achieved and Solutions Offered

13.7. Use Case 6: Collaboration between Cedars-Sinai Medical Center and Deep 6 AI

13.7.1. Cedars-Sinai Medical Center

13.7.2. Deep 6 AI

13.7.3. Business Needs

13.7.4. Objectives Achieved and Solutions Offered

13.8. Use Case 7: Collaboration between GlaxoSmithKline (GSK) and PathAI

13.8.1. PathAI

13.8.2. GlaxoSmithKline (GSK)

13.8.3. Business Needs

13.8.4. Objectives Achieved and Solutions Provided

13.9. Use Case 8: Collaboration between Bristol Myers Squibb (BMS) and Concert AI

13.9.1. Concert AI

13.9.2. Bristol Myers Squibb (BMS)

13.9.3. Business Needs

13.9.4. Objectives Achieved and Solutions Provided

+ 14. VALUE CREATION FRAMEWORK: A STRATEGIC GUIDE TO ADDRESS UNMET NEEDS IN CLINICAL TRIALS

14.1. Chapter Overview

14.2. Unmet Needs in Clinical Trials

14.3. Key Assumptions and Methodology

14.4. Key Tools and Technologies

14.4.1. Blockchain

14.4.2. Big Data Analytics

14.4.3. Real-world Evidence

14.4.4. Digital Twins

14.4.5. Cloud Computing

14.4.6. Internet of Things (IoT)

14.5. Trends in Research Activity

14.6. Trends in Intellectual Capital

14.7. Extent of Innovation versus Associated Risks

14.8. Results and Discussion

+ 15. COST SAVING ANALYSIS

15.1. Chapter Overview

15.2. Key Assumptions and Methodology

15.3. Overall Cost Saving Potential Associated with Use of AI in Clinical Trials, Till 2035

15.3.1. Cost Saving Potential: Distribution by Trial Phase, 2026 and 2035

15.3.1.1. Cost Saving Potential in Phase I Clinical Trials, Till 2035

15.3.1.2. Cost Saving Potential in Phase II Clinical Trials, Till 2035

15.3.1.3. Cost Saving Potential in Phase III Clinical Trials, Till 2035

15.3.2. Cost Saving Potential: Distribution by Trial Procedure, 2026 and 2035

15.3.2.1. Cost Saving Potential in Patient Recruitment, Till 2035

15.3.2.2. Cost Saving Potential in Staffing and Administration, Till 2035

15.3.2.3. Cost Saving Potential in Site Monitoring, Till 2035

15.3.2.4. Cost Saving Potential in Source Data Verification, Till 2035

15.3.2.5. Cost Saving Potential in Patient Retention, Till 2035

15.3.2.6. Cost Saving Potential in Other Procedures, Till 2035

15.4. Conclusion

+ 16. MARKET IMPACT ANALYSIS

16.1. Chapter Overview

16.2. Market Drivers

16.3. Market Restraints

16.4. Market Opportunities

16.5. Market Challenges

16.6. Conclusion

+ 17. GLOBAL AI IN CLINICAL TRIALS MARKET

17.1. Chapter Overview

17.2. Key Assumptions and Methodology

17.3. Global AI in Clinical Trials Market: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

17.3.1. Scenario Analysis

17.3.1.1. Conservative Scenario

17.3.1.2. Optimistic Scenario

17.4. Key Market Segmentation

+ 18. AI IN CLINICAL TRIALS MARKET, BY TRIAL PHASE

18.1. Chapter Overview

18.2. Key Assumptions and Methodology

18.3. AI in Clinical Trials Market: Distribution by Trial Phase

18.3.1. AI in Clinical Trials Market for Phase I: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

18.3.2. AI in Clinical Trials Market for Phase II: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

18.3.3. AI in Clinical Trials Market for Phase III: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

18.4. Data Triangulation and Validation

+ 19. AI IN CLINICAL TRIALS MARKET, BY TYPE OF OFFERING

19.1. Chapter Overview

19.2. Key Assumptions and Methodology

19.3. AI in Clinical Trials Market: Distribution by Type of Offering

19.3.1. AI in Clinical Trials Market for Software: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

19.3.2. AI in Clinical Trials Market for Services: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

19.4. Data Triangulation and Validation

+ 20. AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE

20.1. Chapter Overview

20.2. Key Assumptions and Methodology

20.3. AI in Clinical Trials Market: Distribution by Deployment Mode

20.3.1. AI in Clinical Trials Market for Cloud-based Deployment: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

20.3.2. AI in Clinical Trials Market for On-premises Deployment: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

20.4. Data Triangulation and Validation

+ 21. AI IN CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA

21.1. Chapter Overview

21.2. Key Assumptions and Methodology

21.3. AI in Clinical Trials Market: Distribution by Therapeutic Area

21.3.1. AI in Clinical Trials Market for Oncological Disorders: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

21.3.2. AI in Clinical Trials Market for Infectious Diseases: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

21.3.3. AI in Clinical Trials Market for CNS Disorders: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

21.3.4. AI in Clinical Trials Market for Metabolic Disorders: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

21.3.5. AI in Clinical Trials Market for Immunological Disorders: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

21.3.6. AI in Clinical Trials Market for Cardiovascular Disorders: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

21.3.7. AI in Clinical Trials Market for Other Disorders: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

21.4. Data Triangulation and Validation

+ 22. AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY EXPOSURE

22.1. Chapter Overview

22.2. Key Assumptions and Methodology

22.3. AI in Clinical Trials Market: Distribution by Technology Exposure

22.3.1. AI in Clinical Trials Market for Machine Learning: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

22.3.2. AI in Clinical Trials Market for Molecular Modeling and Simulation: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

22.3.3. AI in Clinical Trials Market for Deep Learning: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

22.3.4. AI in Clinical Trials Market for Omics Integration: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

22.3.5. AI in Clinical Trials Market for Generative Model: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

22.3.6. AI in Clinical Trials Market for Other Technologies: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

22.4. Data Triangulation and Validation

+ 23. AI IN CLINICAL TRIALS MARKET, BY END-USER

23.1. Chapter Overview

23.2. Key Assumptions and Methodology

23.3. AI in Clinical Trials Market: Distribution by End-user

23.3.1. AI in Clinical Trials Market for Biotechnology and Pharmaceutical Companies: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

23.3.2. AI in Clinical Trials Market for Academic Research Institutes and Other End-users: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

23.4. Data Triangulation and Validation

+ 24. AI IN CLINICAL TRIALS MARKET, BY GEOGRAPHICAL REGIONS

24.1. Chapter Overview

24.2. Key Assumptions and Methodology

24.3. AI in Clinical Trials Market: Distribution by Geographical Regions

24.3.1. AI in Clinical Trials Market in North America: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

24.3.1.1. AI in Clinical Trials Market in the US: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

24.3.1.2. AI in Clinical Trials Market in Canada: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

24.3.2. AI in Clinical Trials Market in Europe: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

24.3.2.1. AI in Clinical Trials Market in the UK: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

24.3.2.2. AI in Clinical Trials Market in Germany: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

24.3.2.3. AI in Clinical Trials Market in France: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

24.3.2.4. AI in Clinical Trials Market in Spain: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

24.3.2.5. AI in Clinical Trials Market in Italy: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

24.3.2.6. AI in Clinical Trials Market in Rest of Europe: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

24.3.3. AI in Clinical Trials Market in Asia-Pacific: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

24.3.3.1. AI in Clinical Trials Market in China: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

24.3.3.2. AI in Clinical Trials Market in Japan: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

24.3.3.3. AI in Clinical Trials Market in South Korea: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

24.3.3.4. AI in Clinical Trials Market in Australia: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

24.3.3.5. AI in Clinical Trials Market in India: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

24.3.4. AI in Clinical Trials Market in Middle East and North Africa: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

24.3.4.1. AI in Clinical Trials Market in Saudi Arabia: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

24.3.4.2. AI in Clinical Trials Market in UAE: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

24.3.4.3. AI in Clinical Trials Market in Egypt: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

24.3.5. AI in Clinical Trials Market in Latin America: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

24.3.5.1. AI in Clinical Trials Market in Brazil: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

24.3.5.2. AI in Clinical Trials Market in Mexico: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

24.3.5.3. AI in Clinical Trials Market in Argentina: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

24.4. Market Dynamics Assessment

24.4.1. Market Movement Analysis

24.4.2. Penetration-Growth (P-G) Matrix

24.5. Data Triangulation and Validation

+ 25. MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA

25.1. AI in Clinical Trials Market in North America: Distribution by Trial Phase

25.1.1. AI in Clinical Trials Market in North America for Phase I, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

25.1.2. AI in Clinical Trials Market in North America for Phase II, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

25.1.3. AI in Clinical Trials Market in North America for Phase III, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

25.2. AI in Clinical Trials Market in North America: Distribution by Type of Offering

25.2.1. AI in Clinical Trials Market in North America for Software, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

25.2.2. AI in Clinical Trials Market in North America for Services, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

25.3. AI in Clinical Trials Market in North America: Distribution by Deployment Mode

25.3.1. AI in Clinical Trials Market in North America for Cloud-based Deployment, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

25.3.2. AI in Clinical Trials Market in North America for On-premises Deployment, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

25.4. AI in Clinical Trials Market in North America: Distribution by Therapeutic Area

25.4.1. AI in Clinical Trials Market in North America for Oncological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

25.4.2. AI in Clinical Trials Market in North America for Infectious Diseases, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

25.4.3. AI in Clinical Trials Market in North America for CNS Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

25.4.4. AI in Clinical Trials Market in North America for Metabolic Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

25.4.5. AI in Clinical Trials Market in North America for Immunological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

25.4.6. AI in Clinical Trials Market in North America for Cardiovascular Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

25.4.7. AI in Clinical Trials Market in North America for Other Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

25.5. AI in Clinical Trials Market in North America: Distribution by Technology Exposure

25.5.1. AI in Clinical Trials Market in North America for Machine Learning, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

25.5.2. AI in Clinical Trials Market in North America for Molecular Modeling and Simulation, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

25.5.3. AI in Clinical Trials Market in North America for Deep Learning, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

25.5.4. AI in Clinical Trials Market in North America for Omics Integration, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

25.5.5. AI in Clinical Trials Market in North America for Generative Model, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

25.5.6. AI in Clinical Trials Market in North America for Other Technologies, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

25.6. AI in Clinical Trials Market in North America: Distribution by End-user

25.6.1. AI in Clinical Trials Market in North America for Biotechnology and Pharmaceutical Companies, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

25.6.2. AI in Clinical Trials Market in North America for Academic Research Institutes and Other End-users, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

+ 26. MARKET OPPORTUNITY ANALYSIS: EUROPE

26.1. AI in Clinical Trials Market in Europe: Distribution by Trial Phase

26.1.1. AI in Clinical Trials Market in Europe for Phase I, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

26.1.2. AI in Clinical Trials Market in Europe for Phase II, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

26.1.3. AI in Clinical Trials Market in Europe for Phase III, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

26.2. AI in Clinical Trials Market in Europe: Distribution by Type of Offering

26.2.1. AI in Clinical Trials Market in Europe for Software, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

26.2.2. AI in Clinical Trials Market in Europe for Services, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

26.3. AI in Clinical Trials Market in Europe: Distribution by Deployment Mode

26.3.1. AI in Clinical Trials Market in Europe for Cloud-based Deployment, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

26.3.2. AI in Clinical Trials Market in Europe for On-premises Deployment, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

26.4. AI in Clinical Trials Market in Europe: Distribution by Therapeutic Area

26.4.1. AI in Clinical Trials Market in Europe for Oncological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

26.4.2. AI in Clinical Trials Market in Europe for Infectious Diseases, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

26.4.3. AI in Clinical Trials Market in Europe for CNS Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

26.4.4. AI in Clinical Trials Market in Europe for Metabolic Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

26.4.5. AI in Clinical Trials Market in Europe for Immunological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

26.4.6. AI in Clinical Trials Market in Europe for Cardiovascular Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

26.4.7. AI in Clinical Trials Market in Europe for Other Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

26.5. AI in Clinical Trials Market in Europe: Distribution by Technology Exposure

26.5.1. AI in Clinical Trials Market in Europe for Machine Learning, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

26.5.2. AI in Clinical Trials Market in Europe for Molecular Modeling and Simulation, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

26.5.3. AI in Clinical Trials Market in Europe for Deep Learning, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

26.5.4. AI in Clinical Trials Market in Europe for Omics Integration, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

26.5.5. AI in Clinical Trials Market in Europe for Generative Model, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

26.5.6. AI in Clinical Trials Market in Europe for Other Technologies, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

26.6. AI in Clinical Trials Market in Europe: Distribution by End-user

26.6.1. AI in Clinical Trials Market in Europe for Biotechnology and Pharmaceutical Companies, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

26.6.2. AI in Clinical Trials Market in Europe for Academic Research Institutes and Other End-users, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

+ 27. MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC

27.1. AI in Clinical Trials Market in Asia-Pacific: Distribution by Trial Phase

27.1.1. AI in Clinical Trials Market in Asia-Pacific for Phase I, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

27.1.2. AI in Clinical Trials Market in Asia-Pacific for Phase II, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

27.1.3. AI in Clinical Trials Market in Asia-Pacific for Phase III, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

27.2. AI in Clinical Trials Market in Asia-Pacific: Distribution by Type of Offering

27.2.1. AI in Clinical Trials Market in Asia-Pacific for Software, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

27.2.2. AI in Clinical Trials Market in Asia-Pacific for Services, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

27.3. AI in Clinical Trials Market in Asia-Pacific: Distribution by Deployment Mode

27.3.1. AI in Clinical Trials Market in Asia-Pacific for Cloud-based Deployment, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

27.3.2. AI in Clinical Trials Market in Asia-Pacific for On-premises Deployment, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

27.4. AI in Clinical Trials Market in Asia-Pacific: Distribution by Therapeutic Area

27.4.1. AI in Clinical Trials Market in Asia-Pacific for Oncological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

27.4.2. AI in Clinical Trials Market in Asia-Pacific for Infectious Diseases, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

27.4.3. AI in Clinical Trials Market in Asia-Pacific for CNS Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

27.4.4. AI in Clinical Trials Market in Asia-Pacific for Metabolic Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

27.4.5. AI in Clinical Trials Market in Asia-Pacific for Immunological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

27.4.6. AI in Clinical Trials Market in Asia-Pacific for Cardiovascular Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

27.4.7. AI in Clinical Trials Market in Asia-Pacific for Other Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

27.5. AI in Clinical Trials Market in Asia-Pacific: Distribution by Technology Exposure

27.5.1. AI in Clinical Trials Market in Asia-Pacific for Machine Learning, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

27.5.2. AI in Clinical Trials Market in Asia-Pacific for Molecular Modeling and Simulation, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

27.5.3. AI in Clinical Trials Market in Asia-Pacific for Deep Learning, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

27.5.4. AI in Clinical Trials Market in Asia-Pacific for Omics Integration, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

27.5.5. AI in Clinical Trials Market in Asia-Pacific for Generative Model, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

27.5.6. AI in Clinical Trials Market in Asia-Pacific for Other Technologies, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

27.6. AI in Clinical Trials Market in Asia-Pacific: Distribution by End-user

27.6.1. AI in Clinical Trials Market in Asia-Pacific for Biotechnology and Pharmaceutical Companies, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

27.6.2. AI in Clinical Trials Market in Asia-Pacific for Academic Research Institutes and Other End-users, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

+ 28. MARKET OPPORTUNITY ANALYSIS: MIDDLE EAST AND NORTH AFRICA

28.1. AI in Clinical Trials Market in Middle East and North Africa: Distribution by Trial Phase

28.1.1. AI in Clinical Trials Market in Middle East and North Africa for Phase I, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

28.1.2. AI in Clinical Trials Market in Middle East and North Africa for Phase II, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

28.1.3. AI in Clinical Trials Market in Middle East and North Africa for Phase III, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

28.2. AI in Clinical Trials Market in Middle East and North Africa: Distribution by Type of Offering

28.2.1. AI in Clinical Trials Market in Middle East and North Africa for Software, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

28.2.2. AI in Clinical Trials Market in Middle East and North Africa for Services, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

28.3. AI in Clinical Trials Market in Middle East and North Africa: Distribution by Deployment Mode

28.3.1. AI in Clinical Trials Market in Middle East and North Africa for Cloud-based Deployment, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

28.3.2. AI in Clinical Trials Market in Middle East and North Africa for On-premises Deployment, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

28.4. AI in Clinical Trials Market in Middle East and North Africa: Distribution by Therapeutic Area

28.4.1. AI in Clinical Trials Market in Middle East and North Africa for Oncological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

28.4.2. AI in Clinical Trials Market in Middle East and North Africa for Infectious Diseases, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

28.4.3. AI in Clinical Trials Market in Middle East and North Africa for CNS Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

28.4.4. AI in Clinical Trials Market in Middle East and North Africa for Metabolic Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

28.4.5. AI in Clinical Trials Market in Middle East and North Africa for Immunological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

28.4.6. AI in Clinical Trials Market in Middle East and North Africa for Cardiovascular Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

28.4.7. AI in Clinical Trials Market in Middle East and North Africa for Other Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

28.5. AI in Clinical Trials Market in Middle East and North Africa: Distribution by Technology Exposure

28.5.1. AI in Clinical Trials Market in Middle East and North Africa for Machine Learning, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

28.5.2. AI in Clinical Trials Market in Middle East and North Africa for Molecular Modeling and Simulation, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

28.5.3. AI in Clinical Trials Market in Middle East and North Africa for Deep Learning, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

28.5.4. AI in Clinical Trials Market in Middle East and North Africa for Omics Integration, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

28.5.5. AI in Clinical Trials Market in Middle East and North Africa for Generative Model, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

28.5.6. AI in Clinical Trials Market in Middle East and North Africa for Other Technologies, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

28.6. AI in Clinical Trials Market in Middle East and North Africa: Distribution by End-user

28.6.1. AI in Clinical Trials Market in Middle East and North Africa for Biotechnology and Pharmaceutical Companies, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

28.6.2. AI in Clinical Trials Market in Middle East and North Africa for Academic Research Institutes and Other End-users, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

+ 29. MARKET OPPORTUNITY ANALYSIS: LATIN AMERICA

29.1. AI in Clinical Trials Market in Latin America: Distribution by Trial Phase

29.1.1. AI in Clinical Trials Market in Latin America for Phase I, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

29.1.2. AI in Clinical Trials Market in Latin America for Phase II, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

29.1.3. AI in Clinical Trials Market in Latin America for Phase III, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

29.2. AI in Clinical Trials Market in Latin America: Distribution by Type of Offering

29.2.1. AI in Clinical Trials Market in Latin America for Software, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

29.2.2. AI in Clinical Trials Market in Latin America for Services, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

29.3. AI in Clinical Trials Market in Latin America: Distribution by Deployment Mode

29.3.1. AI in Clinical Trials Market in Latin America for Cloud-based Deployment, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

29.3.2. AI in Clinical Trials Market in Latin America for On-premises Deployment, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

29.4. AI in Clinical Trials Market in Latin America: Distribution by Therapeutic Area

29.4.1. AI in Clinical Trials Market in Latin America for Oncological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

29.4.2. AI in Clinical Trials Market in Latin America for Infectious Diseases, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

29.4.3. AI in Clinical Trials Market in Latin America for CNS Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

29.4.4. AI in Clinical Trials Market in Latin America for Metabolic Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

29.4.5. AI in Clinical Trials Market in Latin America for Immunological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

29.4.6. AI in Clinical Trials Market in Latin America for Cardiovascular Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

29.4.7. AI in Clinical Trials Market in Latin America for Other Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

29.5. AI in Clinical Trials Market in Latin America: Distribution by Technology Exposure

29.5.1. AI in Clinical Trials Market in Latin America for Machine Learning, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

29.5.2. AI in Clinical Trials Market in Latin America for Molecular Modeling and Simulation, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

29.5.3. AI in Clinical Trials Market in Latin America for Deep Learning, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

29.5.4. AI in Clinical Trials Market in Latin America for Omics Integration, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

29.5.5. AI in Clinical Trials Market in Latin America for Generative Model, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

29.5.6. AI in Clinical Trials Market in Latin America for Other Technologies, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

29.6. AI in Clinical Trials Market in Latin America: Distribution by End-user

29.6.1. AI in Clinical Trials Market in Latin America for Biotechnology and Pharmaceutical Companies, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

29.6.2. AI in Clinical Trials Market in Latin America for Academic Research Institutes and Other End-users, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

+ 30. CONCLUDING REMARKS

+ 31. EXECUTIVE INSIGHTS

31.1. Chapter Overview

31.2. Company A

31.2.1. Company Snapshot

31.2.2. Interview Transcript: Co-Founder, Chief Executive Officer and Chief Technology Officer

31.3. Company B

31.3.1. Company Snapshot

31.3.2. Interview Transcript: Founder and Chief Executive Officer

31.4. Company C

31.4.1. Company Snapshot

31.4.2. Interview Transcript: Co-Founder and Executive Director

31.5. Company D

31.5.1. Company Snapshot

31.5.2. Interview Transcript: Founder and Chief Executive Officer

31.6. Company E

31.6.1. Company Snapshot

31.6.2. Interview Transcript: Chief Technology Officer, Chief Commercial Officer, Chief Delivery Officer, Head of Marketing

+ 32. APPENDIX I: TABULATED DATA

+ 33. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

+ List of Figures

Figure 2.1 Research Methodology: Project Methodology

Figure 2.2 Research Methodology: Data Sources for Secondary Research

Figure 2.3 Research Methodology: Robust Quality Control

Figure 3.1 Market Dynamics: Forecast Methodology

Figure 3.2 Market Dynamics: Market Assessment Framework

Figure 4.1 Lessons Learnt from Past Recessions

Figure 5.1 Executive Summary: Market Landscape

Figure 5.2 Executive Summary: Recent Trends

Figure 5.3 Executive Summary: Market Sizing and Opportunity Analysis

Figure 6.1 Types of Algorithms of Machine Learning

Figure 6.2 Applications of AI in Healthcare

Figure 6.3 Examples of AI Platforms / Software Developed by Health-Tech Firms

Figure 6.4 Areas of AI Integration in Clinical Trials

Figure 6.5 Challenges Associated with the Adoption of AI

Figure 7.1 AI in Clinical Trials: Distribution by Year of Establishment

Figure 7.2 AI in Clinical Trials: Distribution by Company Size

Figure 7.3 AI in Clinical Trials: Distribution by Location of Headquarters

Figure 7.4 AI in Clinical Trials: Distribution by Company Size and Location of Headquarters (Region)

Figure 7.5 AI in Clinical Trials: Distribution by Key Offering

Figure 7.6 AI in Clinical Trials: Distribution by Deployment Option

Figure 7.7 AI in Clinical Trials: Distribution by Type of AI Technology Used

Figure 7.8 AI in Clinical Trials: Distribution by End-user

Figure 7.9 AI in Clinical Trials: Distribution by Application Area

Figure 8.1 Clarivate: Annual Revenues, Since 2022

Figure 8.2 IQVIA: Annual Revenues, Since 2022

Figure 8.3 LabCorp: Annual Revenues, Since 2022

Figure 8.4 Dassault Systèmes (Parent Company of Medidata): Annual Revenues, Since 2022

Figure 8.5 Microsoft: Annual Revenues, Since 2022

Figure 8.6 ServiceNow: Annual Revenues, Since 2022

Figure 8.7 TransPerfect Life Sciences: Annual Revenues, Since 2022

Figure 9.1 Clinical Trial Analysis: Distribution by Trial Registration Year, Since 2018

Figure 9.2 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Registration Year, Since 2018

Figure 9.3 Clinical Trial Analysis: Distribution by Trial Phase

Figure 9.4 Clinical Trial Analysis: Distribution by Trial Status

Figure 9.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Status, Since 2018

Figure 9.6 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator

Figure 9.7 Clinical Trial Analysis: Distribution by Patient Gender

Figure 9.8 Clinical Trial Analysis: Distribution by Patient Age

Figure 9.9 Word Cloud Analysis: Emerging Focus Areas

Figure 9.10 Clinical Trial Analysis: Distribution by Target Therapeutic Area

Figure 9.11 Clinical Trial Analysis: Distribution by Type of Patient Allocation Model Used

Figure 9.12 Clinical Trial Analysis: Distribution by Type of Trial Masking Adopted

Figure 9.13 Clinical Trial Analysis: Distribution by Type of Intervention

Figure 9.14 Clinical Trial Analysis: Distribution by Trial Purpose

Figure 9.15 Most Active Players: Distribution by Number of Registered Trials

Figure 9.16 Clinical Trial Analysis: Distribution of Clinical Trials by Geography

Figure 9.17 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Status

Figure 9.18 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Registration Year

Figure 9.19 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Status

Figure 10.1 Partnerships and Collaborations: Distribution by Monthly Trend of Partnership, Since 2025

Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership

Figure 10.3 Partnerships and Collaborations: Distribution by Type of Partner

Figure 10.4 Most Active Players: Distribution by Number of Partnerships

Figure 10.5 Partnerships and Collaborations: Local and International Agreements

Figure 10.6 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements

Figure 11.1 Funding and Investment Analysis: Monthly Trend of Funding Instances

Figure 11.2 Funding and Investment Analysis: Monthly Trend of Amount Invested

Figure 11.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding

Figure 11.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)

Figure 11.5 Funding and Investment Analysis: Distribution by Geography (Region)

Figure 11.6 Funding and Investment Analysis: Distribution by Geography (Country)

Figure 11.7 Most Active Players: Distribution by Number of Funding Instances

Figure 11.8 Leading Investors: Distribution by Number of Funding Instances

Figure 12.1 Big Pharma Initiatives: Distribution by Year of Initiative

Figure 12.2 Big Pharma Initiatives: Distribution by Type of Initiative

Figure 12.3 Heat Map: Distribution by Type of Initiative

Figure 12.4 Big Pharma Initiatives: Distribution by Application Area of AI

Figure 12.5 Heat Map: Distribution by Application Area

Figure 12.6 Big Pharma Initiatives: Distribution by Target Therapeutic Area

Figure 12.7 Heat Map: Distribution by Target Therapeutic Area

Figure 12.8 Benchmarking Analysis: Wind Rose Chart

Figure 13.2 Value Creation Framework: Trends in Research Activity

Figure 13.3 Value Creation Framework: Trends in Intellectual Property

Figure 13.4 Value Creation Framework: Extent of Innovation versus Associated Risk Matrix

Figure 13.5 Value Creation Framework: Harvey Ball Analysis of Key Tools and Technologies

Figure 13.6 Value Creation Framework: Summary

Figure 15.1 Overall Cost Saving Potential Associated with Use of AI in Clinical Trials, Till 2035 (USD Billion)

Figure 15.2 Cost Saving Potential: Distribution by Trial Phase

Figure 15.3 Cost Saving Potential in Phase I Clinical Trials, Till 2035 (USD Billion)

Figure 15.5 Cost Saving Potential in Phase II Clinical Trials, Till 2035 (USD Billion)

Figure 15.5 Cost Saving Potential in Phase III Clinical Trials, Till 2035 (USD Billion)

Figure 15.6 Cost Saving Potential: Distribution by Trial Procedure

Figure 15.7 Cost Saving Potential in Patient Recruitment, Till 2035 (USD Billion)

Figure 15.8 Cost Saving Potential in Staffing and Administration, Till 2035 (USD Billion)

Figure 15.9 Cost Saving Potential in Site Monitoring, Till 2035 (USD Billion)

Figure 15.10 Cost Saving Potential in Source Data Verification, Till 2035 (USD Billion)

Figure 15.11 Cost Saving Potential in Patient Retention, Till 2035 (USD Billion)

Figure 15.12 Cost Saving Potential in Other Procedures, Till 2035 (USD Billion)

Figure 17.1 Global AI in Clinical Trials Market: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 17.2 Global AI in Clinical Trials Market: Forecasted Estimates (Till 2035), Conservative Scenario (USD Billion)

Figure 17.3 Global AI in Clinical Trials Market: Forecasted Estimates (Till 2035), Optimistic Scenario (USD Billion)

Figure 18.1 AI in Clinical Trials Market: Distribution by Trial Phase

Figure 18.2 AI in Clinical Trials Market for Phase I: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 18.3 AI in Clinical Trials Market for Phase II: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 18.4 AI in Clinical Trials Market for Phase III: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 19.1 AI in Clinical Trials Market: Distribution by Type of Offering

Figure 19.2 AI in Clinical Trials Market for Software: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 19.3 AI in Clinical Trials Market for Services: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 20.1 AI in Clinical Trials Market: Distribution by Deployment Mode

Figure 20.2 AI in Clinical Trials Market for Cloud-based Deployment: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 20.3 AI in Clinical Trials Market for On-premises Deployment: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 21.1 AI in Clinical Trials Market: Distribution by Therapeutic Area

Figure 21.2 AI in Clinical Trials Market for Oncological Disorders: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 21.3 AI in Clinical Trials Market for Infectious Diseases: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 21.4 AI in Clinical Trials Market for CNS Disorders: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 21.5 AI in Clinical Trials Market for Metabolic Disorders: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 21.6 AI in Clinical Trials Market for Immunological Disorders: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 21.7 AI in Clinical Trials Market for Cardiovascular Disorders: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 21.8 AI in Clinical Trials Market for Other Disorders: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 22.1 AI in Clinical Trials Market: Distribution by Technology Exposure

Figure 22.2 AI in Clinical Trials Market for Machine Learning: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 22.3 AI in Clinical Trials Market for Molecular Modeling and Simulation: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 22.4 AI in Clinical Trials Market for Deep Learning: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 22.5 AI in Clinical Trials Market for Omics Integration: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 22.6 AI in Clinical Trials Market for Generative Model: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 22.7 AI in Clinical Trials Market for Other Technologies: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 23.1 AI in Clinical Trials Market: Distribution by End-user

Figure 23.2 AI in Clinical Trials Market for Biotechnology and Pharmaceutical Companies: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 23.3 AI in Clinical Trials Market for Academic Research Institutes and Other End-users: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 24.1 AI in Clinical Trials Market: Distribution by Geographical Regions

Figure 24.2 AI in Clinical Trials Market in North America: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 24.3 AI in Clinical Trials Market in the US: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 24.4 AI in Clinical Trials Market in Canada: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 24.5 AI in Clinical Trials Market in Europe: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 24.6 AI in Clinical Trials Market in the UK: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 24.7 AI in Clinical Trials Market in Germany: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 24.8 AI in Clinical Trials Market in France: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 24.9 AI in Clinical Trials Market in Spain: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 24.10 AI in Clinical Trials Market in Italy: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 24.11 AI in Clinical Trials Market in Rest of Europe: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 24.12 AI in Clinical Trials Market in Asia-Pacific: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 24.13 AI in Clinical Trials Market in China: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 24.14 AI in Clinical Trials Market in Japan: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 24.15 AI in Clinical Trials Market in South Korea: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 24.16 AI in Clinical Trials Market in Australia: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 24.17 AI in Clinical Trials Market in India: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 24.18 AI in Clinical Trials Market in Middle East and North Africa: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 24.19 AI in Clinical Trials Market in Saudi Arabia: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 24.20 AI in Clinical Trials Market in UAE: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 24.21 AI in Clinical Trials Market in Egypt: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million

Figure 24.22 AI in Clinical Trials Market in Latin America: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 24.23 AI in Clinical Trials Market in Brazil: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 24.24 AI in Clinical Trials Market in Mexico: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 24.25 AI in Clinical Trials Market in Argentina: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)

Figure 24.26 Market Movement Analysis: Geographical Regions

Figure 24.27 Penetration-Growth (P-G) Matrix: Geographical Regions

Figure 25.1 Concluding Remarks: Overall Market Landscape of AI Software and Service Providers

Figure 25.2 Concluding Remarks: Partnerships and Collaborations

Figure 25.3 Concluding Remarks: Funding and Investment Analysis

Figure 25.4 Concluding Remarks: Market Sizing and Opportunity Analysis (I / II)

Figure 25.5 Concluding Remarks: Market Sizing and Opportunity Analysis (II / II)

+ List of Tables

Table 7.1 AI in Clinical Trials: Information on Year of Establishment, Company Size, and Location of Headquarters

Table 7.2 AI in Clinical Trials: Information on Key Offering and Deployment Option

Table 7.3 AI in Clinical Trials: Information on Type of AI Technology Used

Table 7.4 AI in Clinical Trials: Information on End-user

Table 7.5 AI in Clinical Trials: Information on Application Area

Table 8.1 AI in Clinical Trials: List of Companies Profiled

Table 8.2 Clarivate: Company Overview

Table 8.3 Clarivate: Offerings Portfolio

Table 8.4 Clarivate: Recent Developments and Future Outlook

Table 8.5 ConcertAI: Company Overview

Table 8.6 ConcertAI: Offerings Portfolio

Table 8.7 ConcertAI: Recent Developments and Future Outlook

Table 8.8 IQVIA: Company Overview

Table 8.9 IQVIA: Offerings Portfolio

Table 8.10 IQVIA: Recent Developments and Future Outlook

Table 8.11 LabCorp: Company Overview

Table 8.12 LabCorp: Offerings Portfolio

Table 8.13 LabCorp: Recent Developments and Future Outlook

Table 8.14 Medidata: Company Overview

Table 8.15 Medidata: Offerings Portfolio

Table 8.16 Medidata: Recent Developments and Future Outlook

Table 8.17 Microsoft: Company Overview

Table 8.18 Microsoft: Offerings Portfolio

Table 8.19 Microsoft: Recent Developments and Future Outlook

Table 8.20 PathAI: Company Overview

Table 8.21 PathAI: Offerings Portfolio

Table 8.22 PathAI: Recent Developments and Future Outlook

Table 8.23 ServiceNow: Company Overview

Table 8.24 ServiceNow: Offerings Portfolio

Table 8.25 ServiceNow: Recent Developments and Future Outlook

Table 8.26 Signant Health: Company Overview

Table 8.27 Signant Health: Offerings Portfolio

Table 8.28 Signant Health: Recent Developments and Future Outlook

Table 8.29 TransPerfect Life Sciences: Company Overview

Table 8.30 TransPerfect Life Sciences: Offerings Portfolio

Table 8.31 TransPerfect Life Sciences: Recent Developments and Future Outlook

Table 10.1 AI in Clinical Trials: List of Partnerships and Collaborations, Since 2025

Table 11.1 AI in Clinical Trials: List of Funding and Investments, Since 2025

Table 16.1 Growth Drivers: Market Impact and Time Period

Table 16.2 Growth Restraints: Market Impact and Time Period

Table 16.3 Growth Opportunities: Market Impact and Time Period

Table 16.4 Growth Challenges: Market Impact and Time Period

Table 26.1 Ancora.ai: Company Snapshot

Table 26.2 Deep 6 AI: Company Snapshot

Table 26.3 Intelligencia: Company Snapshot

Table 26.4 nQ Medical: Company Snapshot

Table 26.5 Science 37: Company Snapshot

Table 27.1 AI in Clinical Trials: Distribution by Year of Establishment

Table 27.2 AI in Clinical Trials: Distribution by Company Size

Table 27.3 AI in Clinical Trials: Distribution by Location of Headquarters

Table 27.4 AI in Clinical Trials: Distribution by Company Size and Location of Headquarters (Region)

Table 27.5 AI in Clinical Trials: Distribution by Key Offering

Table 27.6 AI in Clinical Trials: Distribution by Deployment Option

Table 27.7 AI in Clinical Trials: Distribution by Type of AI Technology Used

Table 27.8 AI in Clinical Trials: Distribution by End-user

Table 27.9 AI in Clinical Trials: Distribution by Application Areas

Table 27.10 Clarivate: Annual Revenues, Since 2022

Table 27.11 IQVIA: Annual Revenues, Since 2022

Table 27.12 LabCorp: Annual Revenues, Since 2022

Table 27.13 Dassault Systèmes (Parent Company of Medidata): Annual Revenues, Since 2022

Table 27.14 Microsoft: Annual Revenues, Since 2022

Table 27.15 ServiceNow: Annual Revenues, Since 2022

Table 27.16 TransPerfect Life Sciences: Annual Revenues, Since 2022

Table 27.17 Clinical Trial Analysis: Distribution by Trial Registration Year, Since 2018

Table 27.18 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Registration Year, Since 2018

Table 27.19 Clinical Trial Analysis: Distribution by Trial Phase

Table 27.20 Clinical Trial Analysis: Distribution by Trial Status

Table 27.21 Clinical Trial Analysis: Distribution by Trial Registration Year and Status, Since 2018

Table 27.22 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator

Table 27.23 Clinical Trial Analysis: Distribution by Patient Gender

Table 27.24 Clinical Trial Analysis: Distribution by Patient Age

Table 27.25 Clinical Trial Analysis: Distribution by Target Therapeutic Area

Table 27.26 Clinical Trial Analysis: Distribution by Type of Patient Allocation Model Used

Table 27.27 Clinical Trial Analysis: Distribution by Type of Trial Masking Adopted

Table 27.28 Clinical Trial Analysis: Distribution by Type of Intervention

Table 27.29 Clinical Trial Analysis: Distribution by Trial Purpose

Table 27.30 Most Active Players: Distribution by Number of Registered Trials

Table 27.31 Partnerships and Collaborations: Distribution by Monthly Trend of Partnership, Since 2025

Table 27.32 Partnerships and Collaborations: Distribution by Type of Partnership

Table 27.33 Partnerships and Collaborations: Distribution by Type of Partner

Table 27.34 Most Active Players: Distribution by Number of Partnerships

Table 27.35 Partnerships and Collaborations: Local and International Agreements

Table 27.36 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements

Table 27.37 Funding and Investment Analysis: Monthly Trend of Funding Instances, Since 2025

Table 27.38 Funding and Investment Analysis: Monthly Trend of Amount Invested, Since 2025 (USD Million)

Table 27.39 Funding and Investment Analysis: Distribution of Instances by Type of Funding

Table 27.40 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)

Table 27.41 Funding and Investment Analysis: Distribution by Geography (Country)

Table 27.42 Most Active Players: Distribution by Number of Funding Instances

Table 27.43 Leading Investors: Distribution by Number of Funding Instances

Table 27.44 Big Pharma Initiatives: Distribution by Year of Initiative, Since 2019

Table 27.45 Big Pharma Initiatives: Distribution by Type of Initiative

Table 27.46 Big Pharma Initiatives: Distribution by Application Area of AI

Table 27.47 Big Pharma Initiatives: Distribution by Target Therapeutic Area

Table 27.48 Value Creation Framework: Trends in Research Activity

Table 27.49 Value Creation Framework: Trends in Intellectual Property

Table 27.50 Overall Cost Saving Potential of AI in Clinical Trials, Till 2035 (USD Billion)

Table 27.51 Cost Saving Potential: Distribution by Trial Phase, 2026 and 2035 (USD Billion)

Table 27.52 Cost Saving Potential in Phase I Clinical Trials, Till 2035 (USD Billion)

Table 27.53 Cost Saving Potential in Phase II Clinical Trials, Till 2035 (USD Billion)

Table 27.54 Cost Saving Potential in Phase III Clinical Trials, Till 2035 (USD Billion)

Table 27.55 Cost Saving Potential: Distribution by Trial Procedure, 2026 and 2035 (USD Billion)

Table 27.56 Cost Saving Potential in Patient Recruitment, Till 2035 (USD Billion)

Table 27.57 Cost Saving Potential in Staffing and Administration, Till 2035 (USD Billion)

Table 27.58 Cost Saving Potential in Site Monitoring, Till 2035 (USD Billion)

Table 27.59 Cost Saving Potential in Source Data Verification, Till 2035 (USD Billion)

Table 27.60 Cost Saving Potential in Patient Retention, Till 2035 (USD Billion)

Table 27.61 Cost Saving Potential in Other Procedures, Till 2035 (USD Billion)

Table 27.62 Global AI in Clinical Trials Market, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035): Base Scenario (USD Billion)

Table 27.63 Global AI in Clinical Trials Market, Forecasted Estimates (Till 2035): Conservative Scenario (USD Billion)

Table 27.64 Global AI in Clinical Trials Market, Forecasted Estimates (Till 2035): Optimistic Scenario (USD Billion)

Table 27.65 AI in Clinical Trials Market: Distribution by Trial Phase

Table 27.66 AI in Clinical Trials Market for Phase I: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.67 AI in Clinical Trials Market for Phase II: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.68 AI in Clinical Trials Market for Phase III: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.69 AI in Clinical Trials Market: Distribution by Type of Offering

Table 27.70 AI in Clinical Trials Market for Software: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.71 AI in Clinical Trials Market for Services: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.72 AI in Clinical Trials Market: Distribution by Deployment Mode

Table 27.73 AI in Clinical Trials Market for Cloud-based Deployment: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.74 AI in Clinical Trials Market for On-premises Deployment: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.75 AI in Clinical Trials Market: Distribution by Therapeutic Area

Table 27.76 AI in Clinical Trials Market for Oncological Disorders: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.77 AI in Clinical Trials Market for Infectious Diseases: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.78 AI in Clinical Trials Market for CNS Disorders: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.79 AI in Clinical Trials Market for Metabolic Disorders: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.80 AI in Clinical Trials Market for Immunological Disorders: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.81 AI in Clinical Trials Market for Cardiovascular Disorders: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.82 AI in Clinical Trials Market for Other Disorders: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.83 AI in Clinical Trials Market: Distribution by Technology Exposure

Table 27.84 AI in Clinical Trials Market for Machine Learning: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.85 AI in Clinical Trials Market for Molecular Modeling and Simulation: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.86 AI in Clinical Trials Market for Deep Learning: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.87 AI in Clinical Trials Market for Omics Integration: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.88 AI in Clinical Trials Market for Generative Model: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.89 AI in Clinical Trials Market for Other Technologies: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.90 AI in Clinical Trials Market: Distribution by End-user

Table 27.91 AI in Clinical Trials Market for Biotechnology and Pharmaceutical Companies: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.92 AI in Clinical Trials Market for Academic Research Institute and Other End-users: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.93 AI in Clinical Trials Market: Distribution by Geographical Regions

Table 27.94 AI in Clinical Trials Market in North America: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.95 AI in Clinical Trials Market in the US: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.96 AI in Clinical Trials Market in Canada: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.97 AI in Clinical Trials Market in Europe: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.98 AI in Clinical Trials Market in the UK: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.99 AI in Clinical Trials Market in Germany: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.100 AI in Clinical Trials Market in France: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.101 AI in Clinical Trials Market in Spain: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.102 AI in Clinical Trials Market in Italy: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.103 AI in Clinical Trials Market in Rest of Europe: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.104 AI in Clinical Trials Market in Asia-Pacific: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.105 AI in Clinical Trials Market in China: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.106 AI in Clinical Trials Market in Japan: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.107 AI in Clinical Trials Market in South Korea: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.108 AI in Clinical Trials Market in Australia: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.109 AI in Clinical Trials Market in India: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.110 AI in Clinical Trials Market in Middle East and North Africa: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.111 AI in Clinical Trials Market in Saudi Arabia: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.112 AI in Clinical Trials Market in UAE: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.113 AI in Clinical Trials Market in Egypt: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.114 AI in Clinical Trials Market in Latin America: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.115 AI in Clinical Trials Market in Brazil: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.116 AI in Clinical Trials Market in Mexico: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Table 27.117 AI in Clinical Trials Market in Argentina: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

AI in Clinical Trials Market